From our survey

What caregivers hear about at-home ketamine that is not true

A woman in St. Charles told her sister that her husband was considering ketamine treatment for a depression four medications had not touched. Within a week she had three articles, two ads, and a strong opinion from a coworker whose cousin tried it. None agreed with the others.

That is normal for a caregiver right now. The category is loud, lightly understood, and full of confident claims. Here are five that circulate most, checked against how these treatments are regulated and against the answers of 443 Midwest adults in our June 2026 survey.

Claim one: it is all the same treatment, just delivered differently

This is the most consequential misunderstanding.

Spravato is the brand of esketamine that holds FDA approval, and its label covers adults whose depression did not improve on earlier antidepressants. The patient uses the nasal spray inside a certified health care setting and stays to be monitored afterward. That certification is not the clinic's preference; it is written into how the medication may be used. Brain Recovery Centers describes the supervised Spravato model in plain terms, a useful baseline when you compare anything else.

Generic ketamine prescribed by a telehealth company and mailed to a house is something else. It is used off label for mood, oversight ranges from careful to nearly absent, and it lacks the same approval. A company may call both "ketamine therapy" in the same paragraph. They are not interchangeable, and any talk of cost, safety, or coverage collapses unless you first settle which one is meant.

Claim two: everyone would rather do it from home

We asked respondents how they would prefer to receive this therapy. A clinic in person was the most popular answer at 44 percent. At-home telehealth had 22 percent of the vote and a clinic-to-home hybrid 23; 11 percent had no preference.

So the convenience story is real but a minority view: about two in three respondents wanted a clinic as the whole plan or the starting point. If the person you care for would rather go somewhere and be looked after by staff, that is the most common preference in the sample, not resistance to progress. The results are final, and the ranking is clear.

Claim three: insurance never pays for any of this, so do not bother asking

Whether a plan pays for a treatment is a question for that plan; no website can answer it for your family. What our data shows is how much the answer matters.

Insurance was the deciding factor for 22 percent of respondents and a big factor for 43 percent, 65 percent in all. We also offered a direct trade, coverage with more hoops or paying out of pocket to start sooner, and half picked the hoops; the rest split into 23 percent who would pay and 26 percent who were unsure.

Half this market will put up with paperwork and delay to keep coverage, the opposite of not bothering to ask. Call the plan and ask two things: is esketamine a covered benefit, and is prior authorization required? Then ask the prescribing office who files that paperwork on their side.

Claim four: a session is a quick errand you can fit into a lunch hour

Supervised dosing includes a monitoring period, and a patient who has just been dosed cannot drive home. That is why caregivers end up so central here: someone has to sit in a waiting room and then drive.

Before agreeing to a schedule, ask the clinic for the honest door-to-door length of a visit and the visit count for month one, then set that against your week. From Wentzville, O'Fallon, or the north side of St. Charles, a clinic twenty-five minutes away on a good day and fifty on a bad one is a different commitment weekly than twice weekly. Knowing that early keeps a family from starting what it cannot sustain.

Claim five: if a service advertises heavily, somebody has vetted it

Ad volume tells you about a marketing budget and nothing else, and ads do not seem to persuade people anyway. Only 2 percent of respondents said an ad would get them to try this, against 74 percent for their own doctor and 18 percent for a friend or relative. An online search would be step one for only 12 percent.

If you are the one searching on someone's behalf, put the burden of proof where it belongs. Ask any telehealth provider who the prescriber is and whether that license covers Missouri, what screening comes before a first prescription, who picks up the phone mid-session, how refills and storage work, and what the plan is if nothing improves. Clear answers are the vetting. No other kind is happening for you.

What the survey does not tell you

Ours was a general population survey, not a clinical trial or an outcomes study. It describes what people prefer and what would persuade them. It says nothing about whether a treatment works for a particular person and cannot be used to argue anyone should try anything. That is a clinician's question, answered with the full medication history, other conditions, and risks in view; a website that answers without any of that is selling, not advising.

Where a caregiver's effort actually pays off

The most valuable thing you can do this month is not more reading. It is one page listing every antidepressant the person has tried, how long, and why it stopped, put in front of their own doctor.

You are not alone in needing it. In our survey, 72 percent had lived through, or watched someone close live through, depression, anxiety, or PTSD that ordinary medication could not shift. It is a crowded experience, even if it does not feel that way inside your house, and the medication history is what turns it into something a physician can act on.

Last, and most important: if the person you care for has hinted at not wanting to live, or tonight frightens you, call or text 988. The Lifeline runs around the clock nationwide, and it will talk with you about someone you are worried about, not only with the person in crisis.

Methodology

This publisher commissioned and funded the Pollfish consumer panel survey behind these figures. Fieldwork ended June 23, 2026. By then 443 people, all between 18 and 64 and all living somewhere in a ten-state Midwest region, had answered, each after passing a consent screener. Multi-select items are percentages of all respondents and so add to more than 100. Every number comes from the finished panel validation.